• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.

作者信息

Blackmon Jonathan T, Stratton Michael S, Kwak Young, Pavlidakey Peter G, Slominski Andrzej T, McKee Svetlana B, Viator Toni M, Kim Ju Young, Huang Conway C, Conry Robert M

机构信息

Covenant College, Lookout Mountain, Georgia.

Deparment of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

JAAD Case Rep. 2017 Jun 16;3(4):280-283. doi: 10.1016/j.jdcr.2017.02.011. eCollection 2017 Jul.

DOI:10.1016/j.jdcr.2017.02.011
PMID:28653030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5476450/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a586/5476450/7cc43affd3ec/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a586/5476450/17c48681df45/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a586/5476450/7cc43affd3ec/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a586/5476450/17c48681df45/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a586/5476450/7cc43affd3ec/gr2.jpg

相似文献

1
Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.炎症性黑素瘤发生移行转移，对talimogene laherparepvec完全缓解。
JAAD Case Rep. 2017 Jun 16;3(4):280-283. doi: 10.1016/j.jdcr.2017.02.011. eCollection 2017 Jul.
2
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
3
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.对于在免疫检查点抑制剂和BRAF抑制剂治疗后疾病进展的黑色素瘤患者，talimogene laherparepvec的潜在临床及免疫治疗效用。
Melanoma Res. 2018 Jun;28(3):250-255. doi: 10.1097/CMR.0000000000000444.
4
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.替莫唑胺胶囊：不可切除的转移性黑色素瘤的治疗选择。
BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.
5
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.OPTiM试验中的皮肤头颈黑色素瘤，这是一项随机3期试验，比较talimogene laherparepvec与粒细胞-巨噬细胞集落刺激因子用于治疗不可切除的IIIB/IIIC/IV期黑色素瘤。
Head Neck. 2016 Dec;38(12):1752-1758. doi: 10.1002/hed.24522. Epub 2016 Jul 13.
6
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.从一项多机构的 II 期研究看，黑色素瘤患者接受替莫唑胺拉帕替尼治疗后的全身和局部反应。
J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.
7
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.在黑色素瘤和其他实体瘤中，将talimogene laherparepvec与免疫疗法联合使用。
Cancer Immunol Immunother. 2017 Jun;66(6):683-695. doi: 10.1007/s00262-017-1967-1. Epub 2017 Feb 25.
8
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.最终分析 OPTiM：替莫唑胺联合粒细胞巨噬细胞集落刺激因子对比单用替莫唑胺治疗不能手术的 III-IV 期黑色素瘤的随机 III 期临床试验。
J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.
9
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.替利莫吉因拉赫帕瑞韦克用于不可切除的IIIB-IVM1c期黑色素瘤患者的扩大可及性方案的IIIb期安全性结果
Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399.
10
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.在 IIIB/C 期和 IVM1a 期黑色素瘤患者中，talimogene laherparepvec 与粒细胞巨噬细胞集落刺激因子的疗效和安全性比较：III 期 OPTiM 试验的亚组分析
Onco Targets Ther. 2016 Nov 16;9:7081-7093. doi: 10.2147/OTT.S115245. eCollection 2016.

引用本文的文献

1
Talimogene laherparepvec: First in class oncolytic virotherapy.替莫唑胺：首类溶瘤病毒治疗药物。
Hum Vaccin Immunother. 2018 Apr 3;14(4):839-846. doi: 10.1080/21645515.2017.1412896. Epub 2018 Feb 22.

本文引用的文献

1
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.MITF与c-Jun的拮抗作用将黑色素瘤去分化与促炎细胞因子反应性及髓样细胞募集联系起来。
Nat Commun. 2015 Nov 4;6:8755. doi: 10.1038/ncomms9755.
2
Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?炎症性黑色素瘤的免疫抑制：过继转移的 T 细胞能抵抗吗？
Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.
3
Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in mice.
上皮-间充质转化样和 TGFβ 通路与小鼠自发炎症性黑色素瘤的发展相关。
PLoS One. 2012;7(11):e49419. doi: 10.1371/journal.pone.0049419. Epub 2012 Nov 16.
4
Inflammatory melanoma: a potential diagnostic pitfall.炎症性黑色素瘤：一个潜在的诊断陷阱。
Pathology. 2010;42(6):603-6. doi: 10.3109/00313025.2010.508782.
5
Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.肿瘤引发的炎症会在小鼠诱导性黑色素瘤模型中破坏保护性适应性免疫。
Cancer Res. 2010 May 1;70(9):3515-25. doi: 10.1158/0008-5472.CAN-09-4354. Epub 2010 Apr 20.
6
Cancer-related inflammation.癌症相关炎症
Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205.
7
Inflammatory metastatic melanoma.炎症性转移性黑色素瘤。
J Cutan Pathol. 1999 Feb;26(2):105-8. doi: 10.1111/j.1600-0560.1999.tb01811.x.
8
Melanoma erysipeloides: inflammatory metastatic melanoma of the skin.丹毒样黑色素瘤：皮肤炎性转移性黑色素瘤。
Br J Dermatol. 1993 Sep;129(3):327-9. doi: 10.1111/j.1365-2133.1993.tb11856.x.
9
Inflammatory melanoma.炎性黑色素瘤
J Am Acad Dermatol. 1984 Jan;10(1):52-5. doi: 10.1016/s0190-9622(84)80042-0.